发布时间:
2022
-
03
-
14
点击次数:
0
所属职位：
总裁
所属公司：
杭州多禧生物
个人简介：
赵咏新是美国伊利诺依大学博士。在康奈尔大学和纪念斯隆凯琳癌症中心完成2年博士后工作后，在美国梦山都公司、Pharmacia和美国ImmunoGen公司从事药物研发工作15年。特别是作为核心成员或项目负责人参与了上市药物T-DM1研发工艺优化以及多个ADC药物的设计、研发和工艺优化工作。赵博士于2013年同原ImmunoGen的几位上下游合作的资深科学家全职回国创办杭州多禧生物科技有限公司，从事新一代ADC药物研发工作。目前杭州多禧研发的17款新一代ADC药物分别处在临床试验、中美等国申报、安评、中试优化、药理/药学/药代/毒代评价等等不同阶段。赵博士2014年入选国家人才计划。几年来杭州多禧生物荣获“中国留学人员创业园【最具投资价值企业】”，“浙江省领军型创新创业团队”，2015年科技部火炬杯创新创业大赛浙江赛区生物医药总决赛第一名，全国生物医药行业总决赛第二名”等荣誉。赵博士是“J. Med. Chem.”，“ACS Med. Chem. Lett”和“Bioconj. Chem”期刊的特聘审稿人。其本人多次受邀参加国家、省和市生物医药科技项目和人才计划的评审工作。Robert Zhao btained a PhD from the University of Illinois, USA. After completing 2 years of post-doctoral work at Cornell University and Memorial Sloan-Kettering Cancer Center, he spent 15 years in R&D drug at Montserrat, Pharmacia and ImmunoGen, Inc. In particular, he was involved as a core member or project leader in R&D and process optimization of the marketed T-DM1 drug and several other ADC drugs for clinical trials. In 2013, Dr. Zhao, together with several senior scientists from the former ImmunoGen teams, returned to China full-timely to establish Hangzhou DAC Biotechnology Co. At present, the 17 new generation ADC drugs developed by Hangzhou DAC are in different stages of clinical trial, IND in China, the United States and several other countries, safety evaluation, pilot scale optimization, and efficacy /PK / PD / TK evaluations. Dr. Zhao was selected as a national talent program in 2014. In the past few years, Hangzhou DAC Biotechnology has been awarded as 'Most Valuable Enterprise for Investment in China by the Overseas Chinese Entrepreneurship Parks', 'Leading Innovation and Entrepreneurship Team of Zhejiang Province', “The first place in Zhejiang and The second place nationally in competition for the National Ministry of Science and Technology Torch Cup Innovation and Entrepreneurship in the biomedical science in 2015”. Dr. Zhao is a reviewer for the journals of 'J. Med. Chem.”, “ACS Med. Chem. Lett.' and 'Bioconj Chem”. He has been invited as judges for national, provincial and municipal biomedical science and technology projects and talent programs for many times.